Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766567199> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2766567199 endingPage "A479" @default.
- W2766567199 startingPage "A479" @default.
- W2766567199 abstract "The aim of this study is to compare empagliflozin and standard of care (SoC) for Diabetes mellitus type 2 (T2DM) treatment with a cost-effectiveness analyses in Turkey. In this study, a simulation model designed for time to first cardiovascular (CV) event in T2DM patients was used in the EMPA-REG OUTCOME study population based on health care payer perspective . A cost-effectiveness model was created to stimulate profiles of patients treated with empagliflozin versus patients treated with placebo, both as an adjunct to standard of care (SoC) over a life time horizon. Time dependent survival regression analysis was performed on the EMPA REG OUTCOMES trial data to model event rates over time and the interaction between events. Model outcomes included costs incurred, life years (LY) and quality adjusted life years (QALYs). Future costs and QALYs were discounted at a 3.5% annual rate according to health care payer’s opinion. According to effectiveness results, empagliflozin plus SoC was associated with longer survival (20.06 LY vs 16.72 LY with placebo plus SoC) with an incremental LY 3.34. Moreover, it was designated that the QALYs gained by empagliflozin was 10,13 and the QALYs gain by SoC was 8.90. The incremental QALYs was 1.23. Comparing placebo with empagliflozin’s incremental cost and effectiveness values in the analysis of empagliflozin and cost per patient, the ICER was found as $ 2183.8 per the QALY and it was $ 804.6 per LY gain. According to time the first CV event and survival outcomes of T2DM, empagliflozin is a cost-effective treatment. Probabilistic sensitivity analyses showed with 100% accuracy that empagliflozin is more cost-effective as compared to SoC. Empagliflozin is a cost effective additive treatment over SoC for T2DM patients. The cost-effectiveness results was further confirmed with sensitivity analysis." @default.
- W2766567199 created "2017-11-10" @default.
- W2766567199 creator A5003283304 @default.
- W2766567199 creator A5006600917 @default.
- W2766567199 creator A5018736958 @default.
- W2766567199 creator A5040317065 @default.
- W2766567199 creator A5042284631 @default.
- W2766567199 creator A5053776111 @default.
- W2766567199 creator A5068167131 @default.
- W2766567199 creator A5074087737 @default.
- W2766567199 date "2017-10-01" @default.
- W2766567199 modified "2023-09-27" @default.
- W2766567199 title "Cost-Effectiveness of Empagliflozin (Jardiance®) In The Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) In Turkey Based Empa-Reg Outcome Data" @default.
- W2766567199 doi "https://doi.org/10.1016/j.jval.2017.08.457" @default.
- W2766567199 hasPublicationYear "2017" @default.
- W2766567199 type Work @default.
- W2766567199 sameAs 2766567199 @default.
- W2766567199 citedByCount "3" @default.
- W2766567199 countsByYear W27665671992018 @default.
- W2766567199 countsByYear W27665671992019 @default.
- W2766567199 countsByYear W27665671992020 @default.
- W2766567199 crossrefType "journal-article" @default.
- W2766567199 hasAuthorship W2766567199A5003283304 @default.
- W2766567199 hasAuthorship W2766567199A5006600917 @default.
- W2766567199 hasAuthorship W2766567199A5018736958 @default.
- W2766567199 hasAuthorship W2766567199A5040317065 @default.
- W2766567199 hasAuthorship W2766567199A5042284631 @default.
- W2766567199 hasAuthorship W2766567199A5053776111 @default.
- W2766567199 hasAuthorship W2766567199A5068167131 @default.
- W2766567199 hasAuthorship W2766567199A5074087737 @default.
- W2766567199 hasBestOaLocation W27665671991 @default.
- W2766567199 hasConcept C112930515 @default.
- W2766567199 hasConcept C126322002 @default.
- W2766567199 hasConcept C134018914 @default.
- W2766567199 hasConcept C138411078 @default.
- W2766567199 hasConcept C142724271 @default.
- W2766567199 hasConcept C185592680 @default.
- W2766567199 hasConcept C199289684 @default.
- W2766567199 hasConcept C204787440 @default.
- W2766567199 hasConcept C27081682 @default.
- W2766567199 hasConcept C2775887513 @default.
- W2766567199 hasConcept C2777180221 @default.
- W2766567199 hasConcept C2779900020 @default.
- W2766567199 hasConcept C2780652884 @default.
- W2766567199 hasConcept C2908647359 @default.
- W2766567199 hasConcept C2910068830 @default.
- W2766567199 hasConcept C3019080777 @default.
- W2766567199 hasConcept C515549039 @default.
- W2766567199 hasConcept C555293320 @default.
- W2766567199 hasConcept C71924100 @default.
- W2766567199 hasConcept C99454951 @default.
- W2766567199 hasConceptScore W2766567199C112930515 @default.
- W2766567199 hasConceptScore W2766567199C126322002 @default.
- W2766567199 hasConceptScore W2766567199C134018914 @default.
- W2766567199 hasConceptScore W2766567199C138411078 @default.
- W2766567199 hasConceptScore W2766567199C142724271 @default.
- W2766567199 hasConceptScore W2766567199C185592680 @default.
- W2766567199 hasConceptScore W2766567199C199289684 @default.
- W2766567199 hasConceptScore W2766567199C204787440 @default.
- W2766567199 hasConceptScore W2766567199C27081682 @default.
- W2766567199 hasConceptScore W2766567199C2775887513 @default.
- W2766567199 hasConceptScore W2766567199C2777180221 @default.
- W2766567199 hasConceptScore W2766567199C2779900020 @default.
- W2766567199 hasConceptScore W2766567199C2780652884 @default.
- W2766567199 hasConceptScore W2766567199C2908647359 @default.
- W2766567199 hasConceptScore W2766567199C2910068830 @default.
- W2766567199 hasConceptScore W2766567199C3019080777 @default.
- W2766567199 hasConceptScore W2766567199C515549039 @default.
- W2766567199 hasConceptScore W2766567199C555293320 @default.
- W2766567199 hasConceptScore W2766567199C71924100 @default.
- W2766567199 hasConceptScore W2766567199C99454951 @default.
- W2766567199 hasIssue "9" @default.
- W2766567199 hasLocation W27665671991 @default.
- W2766567199 hasOpenAccess W2766567199 @default.
- W2766567199 hasPrimaryLocation W27665671991 @default.
- W2766567199 hasRelatedWork W2544340838 @default.
- W2766567199 hasRelatedWork W2588682962 @default.
- W2766567199 hasRelatedWork W2610912351 @default.
- W2766567199 hasRelatedWork W2893676915 @default.
- W2766567199 hasRelatedWork W2906462614 @default.
- W2766567199 hasRelatedWork W2906642016 @default.
- W2766567199 hasRelatedWork W2981016494 @default.
- W2766567199 hasRelatedWork W2981371482 @default.
- W2766567199 hasRelatedWork W3085325173 @default.
- W2766567199 hasRelatedWork W4251115415 @default.
- W2766567199 hasVolume "20" @default.
- W2766567199 isParatext "false" @default.
- W2766567199 isRetracted "false" @default.
- W2766567199 magId "2766567199" @default.
- W2766567199 workType "article" @default.